CCEL — Cryo-Cell International Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousMicro CapSuper Stock

Annual income statement for Cryo-Cell International, fiscal year end - November 30th, USD millions except per share, conversion factor applied.

	2020 November 30th	C2021 November 30th	2022 November 30th	2023 November 30th	2024 November 30th
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	31.1	28.9	30.3	31.3	32
Cost of Revenue
Gross Profit	21.5	19.9	21.5	22.9	24
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	24.6	24.9	26.3	43.6	28.5
Operating Profit	6.59	4.02	4.02	-12.3	3.48
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	5.04	2.61	3.32	-13.4	2.8
Provision for Income Taxes
Net Income After Taxes	3.62	2.08	2.77	-9.52	0.402
Net Income Before Extraordinary Items
Net Income	3.62	2.08	2.77	-9.52	0.402
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3.62	2.08	2.77	-9.52	0.402
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	0.653	0.362	0.287	0.171	0.073
Special Dividends per Share